BMCL Digest
Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus

https://doi.org/10.1016/j.bmcl.2014.05.019Get rights and content

Abstract

Despite the availability of established medication for treatment of type 2 diabetes mellitus (T2DM) there still remains a significant unmet need for new effective, oral antidiabetic agents that improve glycemic control while maintaining an excellent safety profile. In this regard the FFA1 receptor has emerged as an attractive target in recent years. Activation of the FFA1 receptor has been shown to not only amplify glucose induced insulin secretion from pancreatic beta cells but also to stimulate incretin secretion from intestinal endocrine cells. The current review highlights on the latest developments and clinical data from evolving research on the potential of FFA1 agonists as effective treatment for T2DM.

References and notes (91)

  • M. Lorenz et al.

    Bioorg. Med. Chem. Lett.

    (2013)
  • K. Nakamoto et al.

    Brain Res.

    (2012)
  • H. Hu et al.

    Biochem. Biophys. Res. Commun.

    (2009)
  • X. Zhang et al.

    Biomed. Pharmacother.

    (2010)
  • P. Steneberg et al.

    Cell Metab.

    (2005)
  • V. Poitout et al.

    Drug Discovery Today

    (2013)
  • A.D. Mancini et al.

    Trends Endocrinol. Metab.

    (2013)
  • E. Le Poul et al.

    J. Biol. Chem.

    (2003)
  • C.F. Burant et al.

    Lancet

    (2012)
  • J.B. Houze et al.

    Bioorg. Med. Chem. Lett.

    (2012)
  • Y. Xiong et al.

    Mol. Cell. Endocrinol.

    (2013)
  • H. Tanaka et al.

    Life Sci.

    (2014)
  • H. Lu et al.

    Bioorg. Med. Chem. Lett.

    (2013)
  • S.P. Walsh et al.

    Bioorg. Med. Chem. Lett.

    (2011)
  • Diabetes factsheet from WHO providing key facts and information on types of diabetes, symptoms, common consequences,...
  • National DiabetesFactSheet, 2011.http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf Center for Disease Control and...
  • B. Ahrén

    Nat. Rev. Drug Discovery

    (2009)
  • B. Ahrén

    Expert Opin. Emerging Drugs

    (2008)
  • S. Edfalk et al.

    Diabetes

    (2008)
  • P. Sun et al.

    PLoS ONE

    (2013)
  • M. Kebede et al.

    Diabetes

    (2008)
  • C.F. Burant

    Diabetes Care

    (2013)
  • M. Ferdaoussi et al.

    Diabetologia

    (2012)
  • T. Hira et al.

    Am. J. Physiol. Gastrointest. Liver Physiol.

    (2009)
  • J. Luo et al.

    PLoS ONE

    (2012)
  • D.J. Drucker et al.

    Proc. Natl. Acad. Sci. U.S.A.

    (1987)
  • Y. Itoh et al.

    Nature

    (2003)
  • J.B. Houze
  • N. Negoro et al.

    ACS Med. Chem. Lett.

    (2010)
  • T. Araki et al.

    Diabetes Obes. Metab.

    (2012)
  • H. Naik et al.

    J. Clin. Pharmacol.

    (2012)
  • K. Kaku et al.

    Diabetes Care

    (2013)
  • Kaku, K.; Enya, K.; Nakaya, R.; Ohira, T.; Matsuno, R. Presented at the 49th EASD, Barcelona, Spain, September 2013 PS...
  • Takeda: http://clinicaltrials.gov/ct2/show/NCT01834274 Comparison of TAK-875 With Sitagliptin When Used in Combination...
  • Takeda: http://clinicaltrials.gov/show/NCT01481116 Efficacy and Safety of TAK-875 Compared to Glimepiride When Used...
  • Takeda: http://clinicaltrials.gov/show/NCT01829464 TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With...
  • Takeda Press release Dec 27th, 2013:...
  • C. Yabuki et al.

    PLoS ONE

    (2013)
  • Japan Tobacco: http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-121730 A Phase 2 Study of...
  • Japan Tobacco: http://clinicaltrials.gov/show/NCT01699737 Safety and Efficacy Study of JTT-851 in Patients With Type 2...
  • Shimada, T.; Ueno, H.; Tsutsumi, K.; Aoyagi, K.; Manabe, T.; Sasaki, S.; Katoh, S. WO 2009/054479,...
  • Piramal Pipeline:...
  • Piramal: http://www.pharmabiz.com/NewsDetails.aspx?aid=75330&sid=2 Piramal receives US FDA approval for anti-diabetic...
  • 40 Piramal: http://clinicaltrials.gov/show/NCT01874366 Determination of Safety,Tolerability,Pharmacokinetics,Food...
  • Kumar, S.; Sharma, R.; Mahajan, V.; Sawargave, S. WO 2013/128378,...
  • Cited by (0)

    View full text